The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.

Journal of Clinical and Translational Hepatology is an esteemed publication dedicated to advancing the field of hepatology through innovative research and clinical insights. Published by XIA & HE PUBLISHING INC, this journal connects researchers and healthcare professionals in the exploration of liver diseases and their management. With an impact factor that reflects its significant contribution to the discipline, the Journal holds a commendable Q2 classification in Hepatology as of 2023, and it ranks highly in both Gastroenterology and Hepatology categories on Scopus, positioning it within the top 80th percentile of its field. Although the journal is not open access, it provides its audience with invaluable information, encouraging collaboration that aims to translate clinical findings into transformative patient care. With a publication history spanning from 2013 to 2024, the Journal of Clinical and Translational Hepatology has established itself as a vital resource for researchers, clinicians, and students alike, making it a prominent voice in the hepatological community.

The International Journal of Hepatology, published by HINDAWI LTD, is a premier open-access journal dedicated to the field of hepatology. Since its inception, this journal has championed the dissemination of cutting-edge research and reviews pertaining to liver health, diseases, and therapies. With an ISSN of 2090-3448, the journal has been committed to open-access publishing since 2011, ensuring that vital knowledge is readily available to researchers, clinicians, and students worldwide. Based in Egypt, this journal stands out in its category, achieving a Q3 ranking in 2023 within the scope of Hepatology by Scopus, which ranks it #43 out of 82 in the field. The International Journal of Hepatology offers a platform for significant findings and discussions that influence clinical practices and foster new research directions, thus playing a crucial role in advancing the understanding of liver diseases and their management.

Canadian Journal of Gastroenterology and Hepatology, published by HINDAWI LTD, serves as a vital resource in the fields of gastroenterology and hepatology. Since its inception in 1987, this open-access journal has made significant contributions to advancing research and clinical practice through its comprehensive coverage of topics ranging from liver diseases to gastrointestinal disorders. With an impressive Q2 ranking in Gastroenterology and a Q3 ranking in Hepatology as of 2023, the journal has established itself as an influential platform for researchers and healthcare professionals seeking to disseminate and acquire knowledge. The journal is based in Egypt, with its operational headquarters located in London, England. Notably, it holds a respectable standing in Scopus rankings, placed at Rank #64 in Gastroenterology and Rank #34 in Hepatology, reflecting its impact and relevance in the medical community. With a commitment to quality and accessibility, the Canadian Journal of Gastroenterology and Hepatology continues to foster innovation and collaboration among its readers.

Clinics in Liver Disease is an esteemed peer-reviewed journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of hepatology. Established in 1997 and covering a broad range of topics within liver disease research, this journal serves as a vital resource for researchers, clinicians, and students engaged in the study of liver health and diseases. With a commendable impact factor placing it within the Q2 category in Hepatology and ranking #32 out of 82 in the Scopus classifications, it consistently disseminates high-quality research and clinical insights. The journal’s commitment to promoting understanding and management of liver diseases is reflected in its rigorous editorial standards and comprehensive review processes. Although not an open-access publication, Clinics in Liver Disease offers subscription options that ensure accessibility to up-to-date research and reviews critical for both academic and clinical success.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

Korean Journal of Gastroenterology (ISSN: 1598-9992, E-ISSN: 2233-6869), published by the Korean Society of Gastroenterology, has been a premier outlet for research and advancements in the field of gastroenterology since its inception in 1968. This open-access journal, based in South Korea, fosters a global dialogue on gastrointestinal health, embracing contributions from a diverse array of disciplines within medicine. It is currently ranked in the Q4 quartile for miscellaneous medicine and holds a Scopus rank of #323 out of 636 in general medicine, reflecting its commitment to publishing impactful research despite its relatively recent establishment in high-impact metrics. With a continuous publication timeline extending through to 2024, the journal aims to enhance understanding of gastrointestinal disorders and promote innovative treatments, making it an essential resource for researchers, clinicians, and students alike who seek to stay abreast of the latest developments and clinical applications in gastroenterology.

BMJ Open Gastroenterology is a premier open access journal published by the esteemed BMJ Publishing Group, focusing on the dynamic and evolving field of gastroenterology. Established in 2014, the journal has rapidly ascended in stature, reflected in its impressive 2023 Q1 ranking in gastroenterology and its position within the top 25% of journals in the category according to Scopus. With a mission to disseminate high-quality, peer-reviewed research with global significance, the journal provides a vital platform for researchers, professionals, and students alike to share their findings and advancements in gastrointestinal medicine. Operating from its headquarters in London, England, the journal's open access format ensures wide visibility and accessibility of cutting-edge research, making it an invaluable resource for those dedicated to improving patient care and driving innovation in gastroenterological sciences. By engaging with this journal, contributors and readers can stay at the forefront of critical developments in the field, fostering a collaborative environment for knowledge exchange.

DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.